Reata's drug approved yesterday also in Europe 4q23 USA 55.9M sales
SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available during the second
quarter of 2023 and began recognizing SKYCLARYS revenue in the United States during the fourth quarter of 2023, following our acquisition.
https://investors.biogen.com/news-r...rts-fourth-quarter-and-full-year-2023-results
Reata's drug approved yesterday also in Europe 4q23 USA 55.9M...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |